Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Materials Select Sector SPDR Fund (XLB) Price & Performance

BioNTech SE - ADRTrade
Materials Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Materials Select Sector SPDR Fund — how do they compare? BioNTech SE - ADR trades at $93.08 (market cap $23.31B), while Materials Select Sector SPDR Fund trades at $52.79. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BNTXXLB
Market Cap
$23.31B
Sector
Health
52-Week High
$119.34$53.62
52-Week Low
$83.89$42.23
Enterprise Value
$6.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.

The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.

Materials Select Sector SPDR Fund

XLB trades at $53.14, showing minimal daily movement with a slight decline of 0.08%. Technical indicators signal a bullish trend with strong moving average support and oscillators showing mixed signals. The materials sector ETF benefits from infrastructure spending and AI-related demand, though recent articles suggest the cyclical recovery may be largely priced in. Dividend payments are scheduled for 2026.

The outlook for XLB remains positive due to sector tailwinds from infrastructure and manufacturing trends, though valuation concerns exist after recent gains. Key risks include cyclical sector exposure and potential overvaluation. Analyst sentiment appears cautiously optimistic with technical strength supporting near-term momentum.

Returns comparison

Trailing returns across standard periods

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Materials Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.

Read more on XLB